Monday, November 7, 2016

BRIEF-Pfizer to present additional research for XELJANZ in rheumatologic diseases

* Pfizer to present additional research for XELJANZ

(tofacitinib citrate) in rheumatologic diseases, including

rheumatoid arthritis and psoriatic arthritis

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)